Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 14, 2024

Responder Analysis Using Clinically Meaningful Thresholds in Patients With Prurigo Nodularis Treated With Dupilumab

Journal of the European Academy of Dermatology and Venereology: JEADV


Additional Info

Journal of the European Academy of Dermatology and Venereology: JEADV
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
J Eur Acad Dermatol Venereol 2024 May 24;[EPub Ahead of Print], SG Kwatra, G Yosipovitch, S Ständer, I Guillemin, J Msihid, A Bansal, M Makhija, S Wiggins, J Zahn, RB Thomas, D Bahloul

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading